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Abstract: Polycystic ovary syndrome (PCOS), a common reproductive endocrine condition 
manifests at puberty, and is characterized by hyperandrogenism, chronic anovulation, and 
obesity. PCOS cases exhibit an adverse coronary heart disease (CHD) proﬁ  le at an early age, 
including insulin resistance, dyslipidemia and increased central adiposity. It can be hypothesized 
that the menopausal transition, whether natural or surgical, may provide an additional “insult”, 
resulting in greater cumulative risk to their vasculature. Coronary artery calciﬁ  cation (CAC), a 
measure of subclinical atherosclerosis (SCA), was measured by electron beam tomography in 
149 PCOS cases and 166 controls (mean age 47.3 and 49.4 respectively). Cases had a higher 
prevalence of CAC (63.1%) compared to controls (41.0%), (p = 0.037) after adjustment for age 
and BMI. A total of 22 cases and 39 controls had undergone natural menopause, 12 cases and 
26 controls underwent surgical menopause (with biochemical conﬁ  rmation) and 115 cases and 
101 controls reported being currently premenopausal. There was a signiﬁ  cant difference in CAC 
values between cases and controls in all three-menopause categories including pre-menopausal, 
surgically induced and natural menopause (p   0.001). Duration since menopause (years) and 
use of hormone replacement therapy were not different between cases and controls for the 
two menopause groups. Logistic regression was carried out with CAC ( 10 vs  10) as the 
dependent variable, and independent variables: PCOS status, current age, BMI, and menopausal 
status, (pre-menopause, surgical and natural menopause) and selected CHD risk factors. The 
data indicate that women with PCOS exhibit signiﬁ  cantly increased CAC compared to controls 
after adjustment for age and BMI and menopausal status. PCOS status and fasting glucose 
were signiﬁ  cant risk factors for CAC (p   0.05). Both natural and surgical menopause were 
independent risk factors for CAC as well (p   0.01). HDLT was of borderline signiﬁ  cance, 
p   0.10. Further follow-up of this cohort will be valuable in determining whether PCOS status 
continues to affect cardiovascular risk as they undergo the menopausal transition.
Keywords: polycystic ovary syndrome, coronary artery calciﬁ  cation, subclinical atherosclerosis, 
coronary vasculature, coronary heart disease risk, menopausal transition
Introduction
PCOS is the most common reproductive endocrine condition affecting 6%–10% of all 
women (Knochenhauer et al 1998; Azziz et al 2004). It is a lifelong condition, which 
manifests at puberty and is characterized by obesity, hyperandrogenism, chronic 
anovulation and menstrual irregularity. Women with PCOS are hyperinsulinemic 
and fully 40% of cases will develop type 2 diabetes by age 50 (Dunaif 1995; Ehrman 
et al 1999). Two recent independent investigations in both younger (25–34) (Christian 
et al 2003) and older (35–62) (Talbott et al 2004) women with PCOS demonstrated an 
increased prevalence of coronary artery calcium (CAC) measured by electron beam Vascular Health and Risk Management 2008:4(2) 454
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tomography. These increases were found to be independent 
of age and body mass index. These ﬁ  ndings reﬂ  ect structural 
changes in the coronary vasculature. However other research-
ers (Lakhani et al 2004; Orio et al 2004; Vural et al 2004; 
Meyer et al 2005) have also noted signiﬁ  cant functional 
changes in young PCOS cases compared to controls reﬂ  ected 
in reduced endothelial function and pulse wave velocity. 
The results of these studies may reﬂ  ect an early metabolic 
process, or “insult” beginning much earlier than in normal 
menstruating women.
There is a well-documented loss of the coronary 
protection noted in numerous studies of middle-aged women 
as they enter the menopausal transition (Sutton-Tyrrell 
et al 1998; Matthews et al 1989). At issue is whether this 
further insult promulgated on PCOS women results in a 
cumulative or additive effect on the prevalence of subclinical 
atherosclerosis. This may be reﬂ  ected in increased central 
adiposity, increases in LDL, reduced HDLt and increased 
prevalence of hypertension. No study to date has considered 
the effect of menopause on women with PCOS.
Within the backdrop of this recent information on lifelong 
metabolic problems of younger PCOS women as they 
approach middle age, it can be hypothesized that as PCOS 
cases reach the menopausal transition, a second metabolic 
“insult” may be associated with a greater cumulative risk to 
their vasculature and increased subclinical atherosclerosis 
(SCA). Given the increase in CAC noted in these two 
smaller independent studies, the present study will consider 
the prevalence of CAC using EBT in a large group of 
well-characterized women with PCOS 35–60 years of age 
(N = 149) and normal controls (N = 166).
We hypothesize that women with PCOS cases compared 
to controls will (1) exhibit a greater increased prevalence of 
CAC independent of age and BMI, and further (2) that the 
menopausal transition will be associated with an increased 
prevalence of CAC in PCOS cases compared to controls. 
PCOS is a common condition and one that can potentially 
account for a signiﬁ  cant amount of premature coronary heart 
disease in middle-aged women.
Methods
Study population
Details on the identiﬁ  cation and recruitment of the original 
Pittsburgh PCOS cohort have been reported elsewhere (Talbott 
et al 1995). Briefly, women with PCOS were identified 
largely from two sources of records: (1) the practice records 
of physicians in the 1970–1993, and (2) through recruitment 
efforts aimed at private practices and the local chapter of the 
PCOSA support group with physician conﬁ  rmation. A clinical 
diagnosis of PCOS was established at baseline if there was 
(1) a history of chronic anovulation in association with either 
(2) evidence of clinical (hirsutism) or biochemical (total 
testosterone level greater than 2.0 nmol/L) hyperandrogenism, 
or (3) a luteinizing hormone: follicle stimulating hormone ratio 
(LH:FSH) greater than 2.0. Originally, age- ( ± 5 years) and 
race-matched neighborhood control subjects were selected 
by using a combination of voter’s registration tapes from the 
Greater Pittsburgh area and Cole’s Cross Reference Directory 
of Households (Cole’s Cross Reference Directory 1993). The 
control population has continued to be of similar age and 
socioeconomic and ethnic status. In the present study, women 
with PCOS and controls who were 35–60 years of age were 
eligible for recruitment and invited to undergo non-invasive 
EBT of the coronary arteries (2003–2004). Also, any subject 
reporting a history of Type 1 (insulin-dependent) diabetes was 
excluded. A total of 149 cases and 166 controls were included 
in the baseline EBT and screening.
Risk factor assessment
Detailed data collection and laboratory methodologies have 
been published previously (Talbott et al 1995). Brieﬂ  y, 
height was measured to the nearest half inch on a wall 
mounted Harpenden stadiometer; weight was measured to 
the nearest half pound. BMI, a measure of relative obesity, 
was calculated as a mathematical function of weight and 
height (kg/m2). Waist and hip circumferences (in cm) were 
measured in duplicate with an inelastic tape at the level of the 
umbilicus and greater trochanter, respectively; the average 
value was recorded. The waist: hip ratio was calculated as 
the waist circumference divided by the hip circumference. 
Blood pressure was assessed in duplicate after a 30-minute 
caffeine restriction and 5-minute rest using a random-zero 
sphygmomanometer. A questionnaire was administered 
that included the evaluation of medical, surgical, menstrual 
and reproductive histories, current medication use, lifestyle 
factors, and family history of PCOS.
A 12-hour fasting blood sample was obtained for lipid and 
hormone assays. Serum concentrations of total cholesterol, 
HDLT, HDL2, and triglycerides were measured in the Heinz 
Lipid Laboratory at the University of Pittsburgh. Total cho-
lesterol was determined by the enzymatic method of Allain 
et al (1974). HDLT was determined by the method above 
after selective precipitation by heparin/manganese and the 
removal by centrifugation of VLDL and LDLT. LDLc was 
calculated using the Friedewald formula (Friedewald et al 
1972). Triglycerides were determined using the enzymatic Vascular Health and Risk Management 2008:4(2) 455
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procedure of Bucolo and David (1973). Plasma glucose was 
analyzed by using enzymatic assay (Yellow Springs Glucose 
Analyzer, Yellow Springs Instruments) and plasma insulin 
by radioimmunoassay. Type 2 diabetes history was obtained 
and was deﬁ  ned as either a doctor diagnosis of Type 2 dia-
betes or a fasting blood glucose of  125 mg/dl. History of 
use of cholesterol lowering medications and blood pressure 
medication was also obtained.
Natural menopausal status was deﬁ  ned as not having a 
period for 12 months or more when there was no medical cause 
other than menopause with or without hormone replacement 
therapy. Those who reported a hysterectomy with bilateral 
salpingo oophorectomy (BSO) were classiﬁ  ed as surgical 
menopausal. Women, who reported removal of the uterus with 
one or two ovaries intact were classiﬁ  ed as surgical if they 
reported a history of physician prescribed hormone replace-
ment or had a biochemical proﬁ  le of the reproductive hormones 
indicative of menopause was evaluated. This consisted of a 
FSH level greater that 25 mIU/ml, and a progesterone level 
below 3 ng/ml. This model was adapted from the algorithm 
applied in the WISE study (Women’s Ischemia Syndrome 
Evaluation) (Johnson and Merz 2004). Individuals who did 
not meet these criteria were considered premenopausal.
Coronary calcium assessment
Coronary calcium was assessed at the University of Pittsburgh 
Medical Center (UPMC) Preventive Heart Care Center by 
EBT using the Imatron C-150 Ultrafast CT Scanner (Imatron, 
South San Francisco, CA, USA). For the coronary arteries, 30 
to 40 contiguous 3 mm-thick transverse images were obtained 
from the level of the aortic root to the apex of the heart dur-
ing a maximal breath hold using ECG triggering so that each 
100 millisecond exposure is acquired during the same phase 
of the cardiac cycle (60% of R-R interval). EBT technicians 
were blinded to the case/control status of the subjects. Only 
one scanning sequence was performed in order to minimize 
radiation exposure to the study participants.
Coronary calcium scores were generated using a Base 
Value Region of Interest (BVROI) computer software pro-
gram (AcuImage). All pixels greater than 130 Hounsﬁ  eld 
units and 1 mm2 within an operator deﬁ  ned region of inter-
est in each 3 mm thick image within the coronary arteries 
were considered calciﬁ  ed. The Agatston method was used 
to calculate a calcium score for each region of interest by 
multiplying the area of all signiﬁ  cant pixels by a grade 
number (1, 2, 3, or 4) indicative of the peak CT number 
(ie, Hounsﬁ  eld units). Coronary Artery Calcium volume 
scores were also generated.
Statistical analyses
All statistical analyses were performed using SPSS (version 
13.0). Risk factors were obtained at the same time that the 
EBT was conducted during this 2001–2003 clinical assess-
ment. Demographic, anthropometric, lipid and hormonal 
data were available for analysis from the baseline visit. 
Descriptive statistics, including measures of central tendency 
and dispersion, were computed for all variables of interest 
for PCOS cases and controls and compared using the non-
parametric Mann-Whitney U test for continuous data or a 
chi-square or Fisher’s exact test for categorical data. The 
distribution of coronary artery calcium was markedly skewed 
and could not be normalized using traditional mathematical 
transformations. The prevalence of coronary artery calcium 
was therefore modeled as a binary dichotomous variable.
Univariate logistic regressions was used to identify the 
baseline cardiovascular risk factors, including age, BMI, 
smoking, and hormone use, that potentially predicted CAC 
as the dependent binary variable ( 10 vs  10). Logistic 
regression was conducted to explore the relationship between 
prevalent CAC as the dependent variables and age, BMI and 
PCOS status as independent variables assessed concurrently. 
Variables related to CAC in univariate analysis were included 
in the subsequent models. In the multivariable regression 
modeling, the effect of PCOS on CAC was assessed after 
adjustment for age and BMI.
Results
Baseline and coronary heart disease 
risk factors
A total of 321 women agreed to participate in this phase of 
the study (2000–2003). Results are reported on 315 women 
who met our previously stated age criteria. Participant 
characteristics (smoking status, hormone use, anthropometric 
measures, blood pressure, lipids, and insulin) at the time of 
baseline EBT (2000–2002) are presented by race in Table 1 
for 149 PCOS cases and 166 controls. Fifty African American 
(AA) women (16 PCOS cases and 34 controls) were included 
in this assessment. Women with PCOS were slightly younger 
than control women: 47.3 ± 5.6 (mean ± SD) years for PCOS 
cases and 49.4 ± 5.8 years for control women. There were no 
signiﬁ  cant differences between PCOS cases and controls in 
the prevalence of current smoking, current use of hormones 
or oral contraceptives. PCOS women had higher mean BMI 
(32.6 vs 28.3 kg/m2), and larger waist circumference and 
waist/hip ratio than control women. Average systolic and 
diastolic blood pressures were similar for the two groups. Vascular Health and Risk Management 2008:4(2) 456
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LDL cholesterol was similar for cases and control women; 
however, HDLc cholesterol was lower among PCOS cases 
and triglyceride levels were higher (p   0.05). Mean fasting 
glucose was not signiﬁ  cantly different. However, PCOS 
women had higher mean insulin levels (19.5 vs 13.4 µU/ml) 
(p   0.05). More controls than cases (39.2% vs 22.9%) 
reported being currently postmenopausal, most likely a 
reﬂ  ection of the older age of the controls.
PCOS cases were more likely to report a diagnosis of 
Type 2 diabetes (p   0.05) and use of hypertensive and 
lipid lowering meds (n.s.). White women with PCOS had 
a mean age ± SD of 47.5 ± 5.5 compared to 49.6 ± 5.7 
years for white control women. Cases and controls were 
again similar with regard to current smoking, current use 
of hormones or oral contraceptives. White PCOS cases 
also had a signiﬁ  cantly higher BMI than white controls 
(mean 32.0 v 27.3 kg/m2) and a larger waist circumference 
(94.1 vs 82.9 cm) and waist/hip ratio (0.84 vs 0.79) than 
controls. White PCOS women had higher systolic blood 
pressure compared to controls (p   0.05). Total cholesterol 
(not shown) and LDL cholesterol were similar for case and 
control women; however, HDLc was lower and triglycerides 
were higher among white PCOS cases compared to white 
controls. Moreover, PCOS cases had higher mean insulin 
levels (19.0 vs 12.8 µU/ml) (p   0.05). African American 
(AA) cases were younger than AA controls 46.7 years ± 6.2 
(mean ± SD) years compared to 49.0 ± 6.2 years for control 
women (n.s.). No signiﬁ  cant differences were noted between 
AA cases and controls in current smoking, current use of 
hormones or oral contraceptives. African American PCOS 
women had higher BMI (37.8 vs 32.2 kg/m2) and larger 
waist circumference (103.2 vs 95.0 cm; p = n.s.) than their 
AA control counterparts; however, waist/hip ratio and both 
systolic and diastolic blood pressure showed no signiﬁ  cant 
differences between the two groups.
A total of 22 cases and 39 controls had undergone natu-
ral menopause (no period within 12 months and no surgical 
intervention), 12 cases and 26 controls underwent surgical 
menopause (with biochemical conﬁ  rmation of menopause) 
and 115 cases and 101 controls reported being premenopausal. 
Mean duration of hormone replacement use among cases was 
3.7 years (3.9) and among controls 5.6 years (5.3) n.s.
Table 1 Descriptive statistics at baseline EBT (2000–2003) by race and PCOS status 
  All racesa   White    African  American
  Cases Controls  Cases  Controls  Cases Controls
  n = 149  n = 166  (n = 127)  (n = 132)  (n = 16)  (n = 34)
  (x/SD) (x/SD) (x/SD) (x/SD) (x/SD) (x/SD)
Age, years    47.3b (5.6)  49.4 (5.8)  47.5b (5.5)  49.6 (5.7)  46.7(6.2)  49.0 (6.3)
BMI, kg/m2  32.6b (8.8)  28.3 (6.1)  32.0b (8.4) 27.3  (5.4)  37.8b (9.8)  32.2 (7.1)
Waist/hip ratio  0.84b (0.09)  0.80 (0.08)  0.84b (0.09)  0.79 (0.08)  0.86 (0.08)  0.85 (0.07)
Systolic BP, mm Hg  118.5 (11.2)  116.9 (14.3)  117.9b (11.2)  115.3 (13.4)  123.2 (11.9)  123.2 (16.0)
Diastolic BP, mm Hg  76.2 (8.3)  75.3 (8.4)  76.0 (8.3)  74.2 (8.1)  77.1 (9.0)  79.6 (8.3)
LDLc, mg/dl  123.8 (38.8)  127.4 (32.5)  122.1 (34.3)  128.2 (31.8)  146.3 (68.4)  124.0 (35.6)
HDLc, mg/dl  52.1b (15.0)  57.2 (14.2)  52.3b (15.1)  58.0 (14.5)  49.0 (15.4)  54.2 (12.5)
Triglycerides, mg/dl  126.0b    102.0   128.0b  107.5   92.0   90.0 
(median/range)  (36.0, 1563.0)  (36.0, 479.0)  (36.8, 1563.0)  (45.0, 479.0)  (36.0, 628.0)  36.0, 234.0)
Fasting glucose, mg/dl  98.3 (22.6)  93.3 (11.5)  97.5 (21.1)  92.3 (9.6)  99.9 (17.8)  97.4 (16.6)
Insulin, µU/ml  19.5b (12.2)  13.4 (8.1)  19.0b (11.8)  12.8 (7.8)  22.2b (11.9)  15.9 (9.1)
Duration yrs HRT use  3.7 (3.9)  5.6 (5.3)  3.85 (3.5)  5.26 (4.5)  -  7.87 (8.3)
 (N/%)  (N/%)  (N/%)  (N/%)  (N/%)  (N/%)
Current smoker  25 (16.8)  24 (14.5)  21(16.5)  18 (13.6)  4 (25.0)  6 (17.6)
Current HRT use  18 (12.1)  31 (18.8)  14 (11.0)  23 (17.6)  2 (12.5)  8 (23.5)
Menopause status          
Premenopausal  115 (77.2)  101 (60.8)  96 (75.6)  82 (62.1)  14 (87.5)  19 (55.9)
Natural menopause  22 (14.8)  39 (23.5)  20 (15.7)  32 (24.2)  2 (121.5)  7 (20.6)
Surgical menopause  12 (8.1)  26 (15.7)  11 (8.7)  18 (13.6)  0 (0.0)  8 (23.5)
Type 2 diabetes  18 (12.1)b  3 (1.8)  15 (11.8)b   1 (0.8)  2 (12.5)  2 (5.9)
Hypertension, treated  40 (26.8)  30 (18.1)  33 (26.0)b   16 (12.1)  5 (31.3)  14 (41.2)
Lipid lowering meds  13 (8.7)  7 (4.2)  13 (10.2)  6 (4.5)  0 (0.0)  1 (2.9)
Values are Mean/Count (SD/%).
aIncludes 5 women of other race and 1 woman missing race (all PCOS cases).
bp   0.05 cases vs. controls.  Test of signiﬁ  cance is Mann Whitney for continuous variables; Chi-Square or Fisher Exact for categorical variables.Vascular Health and Risk Management 2008:4(2) 457
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Prevalence of coronary artery calcium 
in PCOS and controls
The prevalence and distribution of CAC is shown for the 
total group and by race in Table 2. The overall prevalence 
of CAC was 63.1% (94/149) among cases and 41% (68/166) 
among controls (p   0.05). The prevalence among white 
PCOS cases was 60.6% versus 35.6% in race-matched 
controls and 93.8% among African American cases com-
pared to 61.8% among AA controls (p   0.05). Moreover, 
a CAC score of greater than 10 was found in 35.5% of cases 
compared to 12.2% of controls (p   0.05). The prevalence 
of CAC Coronary Calcium scores ranged between 1.0 and 
845.5 for 94 PCOS cases and between 1.0 and 211.1 for 86 
controls among all subjects with prevalent CAC. Mean and 
median CAC scores were 26.8 and 3.1 respectively for PCOS 
cases and 6.3 and 0.0 respectively for controls (p   0.05). 
There was a statistically signiﬁ  cant difference in CAC 
values between cases and controls in all three-menopause 
categories: pre-menopausal, surgically induced and natural 
menopause (p   0.001). The median CAC values were 1.42 
and 0.0 for premenopausal, 14.7 compared to 0.0 for natural 
and 24.7 compared to 1.9 in surgical menopausal cases and 
controls respectively.
Hormonal and reproductive 
characteristics of PCOS cases
and controls and the distribution
of coronary artery calciﬁ  cation
Shown in Table 3 are the menopausal characteristics of 
PCOS cases and controls who met the criteria for either a 
natural or surgical menopause. The reported age of natural 
menopause was similar in cases compared to controls with the 
median 50.0 and 48.0 years respectively (n.s.). Duration of 
menopause for those who had undergone a natural menopause 
was 6.7 years vs. 6.3 years (n.s.) among controls. PCOS cases 
reported a younger age at surgical menopause compared to 
controls (42.5 vs 45.0); similarly they demonstrated higher 
CAC scores.
Duration in years since surgical menopause was 10.2 
for cases and 11.7 for controls. Coronary artery calcium 
scores were signiﬁ  cantly greater between cases and con-
trols for both menopausal categories even though the age 
at baseline interview was two years older for cases (52.5 vs 
54.2). Most notable were the elevated FSH levels and very 
low progesterone levels indicative of ovarian failure and 
menopausal status.
Shown in Figures 1–3 are the distributions of median 
CAC scores for cases and controls stratiﬁ  ed by age and 
by menopause status. It can be noted that within the age 
strata  45, Figure 1 (premenopausal shown only) cases do 
not exhibit signiﬁ  cantly greater median CAC compared to 
controls. In both the 45–54 categories and 55+ age strata 
(Figures 2 and 3), menopausal cases contrasted to their 
control counterparts exhibit increased median coronary 
calcium scores. Both natural and surgical PCOS cases 
demonstrate increased median CAC scores in the 45–54 
age category (4.8 vs 0.0 for natural and 16.5 vs. 1.4 for 
controls) n.s. In the oldest age strata, 55+, cases have higher 
median CAC scores than controls in the two menopause 
categories (32.3 compared to 0.00 and 51.8 compared to 
2.6, respectively, p   0.05).
Table 2 Prevalence and distribution of coronary artery calcium score by PCOS status and race
 All  racesa   White    African  American
  PCOS   Controls  PCOS   Controls   PCOS   Controls 
 (N  = 149)  (N = 166)  (N = 127)  (N = 132)  (N = 16)  (N = 34)
Distribution of CAC Agatson Scores            
(N/%)          
0  55 (36.9)  98 (59.0)  50 (39.4)  85 (64.4)  1 (6.3)  13 (38.2)
1–9.9  41 (27.5)  45 (27.1)  38 (29.9)  34 (25.8)  3 (18.8)  11 (32.4)
10–49  35 (23.5)  19 (11.4)  24 (18.9)  9 (6.8)  9 (56.3)  10 (29.4)
50+  18 (12.1)  4 (2.4)  15 (11.8)  4 (3.0)  3 (18.8)  0 (0.0)
Prevalence (any CAC) (N/%)  94 (63.1)b  68 (41.0)  77 (60.6)b  47 (35.6)  15 (93.8)b 21(61.8)
Prevalence (CAC  10) (N/%)   54 (35.5)   20 (12.2)  37 (29.0)  11 (8.5)  12 (75.0)  9 (26.5)
Mean  26.8 6.3 26.2 6.2 39.0 6.8
Median 3.1c 0.0 1.7c 0.0 15.6c 3.6
Range (1–845)  (1–211.1)       
aIncludes 5 women of other race and 1 woman missing race.
bChi square p   0.05 for cases compared to controls.
cM-W test p   0.05 for cases compared to controls.Vascular Health and Risk Management 2008:4(2) 458
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Logistic regression analysis: The logistic regression 
was conducted using a higher threshold of CAC score  10 
versus  10 in a dichotomous fashion. It was believed that 
this would be more appropriate for consideration of clinical 
signiﬁ  cance. The ﬁ  nal models are shown in Tables 4, 5, and 6 
considering age, BMI, PCOS status as well as the menopausal 
categories: pre-menopausal (reference), natural, and surgical. 
Logistic model for cases and controls combined (Table 4) 
demonstrated a signiﬁ  cant contribution of the association with 
coronary artery calciﬁ  cation of  10 versus  10 CAC score 
Figure 1 Median coronary calcium Agatson score in PCOS cases and controls by age ( 45) and menopausal status.
Table 3 Characteristics of post-menopausal PCOS cases and controls
   PCOS  cases      Controls
   Natural  Surgical      Natural  Surgical 
   Menopause  Menopause  Total  Menopause  Menopause  Total
   N  = 22  N = 12  N = 34  N = 39  N = 26  N = 65
Age at EBT   Mean/SD  53.8 (5.2)  50.2 (4.4)  52.5 (5.2)  54.0 (3.5)  54.4 (5.0)  54.2 (4.2)
(years) Median  54.3 49.6 52.8  54.1 54.7  54.2
Age period   Mean/SD  47.0 (8.6)  40.0 (8.6)  44.4 (9.1)  47.7 (4.9)  42.8 (7.0)  45.8 (6.2)
stopped    Median  50.0 42.5 44.5  48.0 45.0  47.0
(years)          
Time since   Mean/SD  6.7 (6.5)  10.2 (9.9)  8.0 (7.9)  6.3 (4.5)  11.7 (7.8)  8.4 (6.5)
menopause    Median  4.9 7.3 5.4  5.2 10.4  6.8
(years)          
CAC score   Median  16.3*  24.7**  18.4*  0.0  1.9  0.0
(Agatson)          
Duration of   Median  4.0 yrs  2.5 yrs    5.0 yrs  5.0 yrs 
hormone use              
(years)          
FSH mIU/ml   Median  38.7  38.3  37.6  84.0  50.3  78.2
(not currently              
on  HRT)          
Progesterone   Median  1.4  2.65  1.5  1.2  1.65  1.3
ng/dl (no HRT)             
Estradiol    Median  39.3  33.1  37.3  28.7  21.3  27.8
pg/ml (no HRT)             
Total   Mean (SD)  1.1 (0.68)  0.93 (3.6)  1.1 (0.63)  0.75 (47)  0.72 (0.09)  0.7 (41)
Testosterone            
ng/dl (no HRT)             
*p   0.05.
**p   0.01 between cases and controls within menopause categories.
1.03
0
0
0.2
0.4
0.6
0.8
1
1.2
Menopausal status
Case
Control
Pre-menopausal
N = 57 N = 39
*
*Not significantVascular Health and Risk Management 2008:4(2) 459
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Figure 2 Median coronary calcium Agatson score in PCOS cases and controls by age (45–54) and menopausal status.
Figure 3 Median coronary calcium Agatson score in PCOS cases and controls by age (55+) and menopausal status.
with PCOS case status (p = 0.032), BMI as well as both surgi-
cal and natural menopause (p = 0.008 and 0.037 respectively) 
in the overall case/control model . When considering PCOS 
cases separately (Table 5); BMI and surgical menopausal 
status with premenopausal status as the reference were signiﬁ  -
cantly related to SCA (CAC values  10 compared to  10) 
and within controls only (Table 6), natural menopause was 
signiﬁ  cantly related to SCA as well as BMI. The parameter 
estimates (odds ratios) for both natural and surgical were both 
elevated when considering cases and controls separately; 
small numbers most likely affected the ﬁ  nal p values.
Discussion
This study comprises one of the largest groups women 
with PCOS followed into middle age as they approach the 
menopause. The present study found that women with PCOS 
have an increased prevalence of CAC (63.1%) compared 
to controls (41.0%) after adjustment for age and BMI 
(p = 0.037). The ﬁ  nal model indicates that individuals (cases 
and controls) who have had a surgical/natural menopause 
have more sub clinical atherosclerosis independent of age and 
BMI and PCOS. PCOS remains a signiﬁ  cant risk factor for 
CAC after adjustment for menopause, age, and BMI. When 
cases were considered separately, surgical menopause inde-
pendent of age and BMI appeared to have the greatest effect 
as an independent risk factor for sub clinical atherosclerosis 
in PCOS cases; whereas among controls natural menopause 
was related to signiﬁ  cantly increased CAC values. Both risk 
estimates (natural and surgical) were elevated in the separate 
models as well as in the combined dataset however. This 
stresses the importance of the menopausal transition, both 
natural and surgical in assessing cardiovascular risk.
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African American PCOS cases were on average heavier and 
had greater median CAC scores than their White counterparts. 
African American PCOS women had greater CAC prevalence 
than African American controls. (p   0.05). In multiple logistic 
regression analysis, ethnicity was not a signiﬁ  cant predictor of 
CAC score independent of PCOS status, age, and BMI.
Fasting glucose was associated with increased CAC 
within cases and controls and lower HDLT was related to 
higher CAC scores within controls only. Moreover, Type 2 
diabetes was reported by PCOS in 12.1% of cases and 1.8% 
of controls (p   0.05). Calculated LDL and triglycerides 
were of borderline signiﬁ  cance as risk factors of SCA in 
PCOS cases and controls.
In the baseline study (Talbott et al l998) of this group 
of women comprised of 243 cases and 243 age matched 
controls, women with PCOS independent of age and BMI 
were found to have increases in cardiovascular risk factors 
in each ten year age strata beginning as early as 19 years of 
age. It was also noted in a second follow-up (1997–1999) of 
this population (Talbott et al 2000), evidence of increased 
average carotid (intima medial wall thickness) IMT among 
women with PCOS (45+ years) compared to control subjects. 
This study involved 125 cases and 142 controls aged 30+ in 
1997–1999. Collection of baseline socio-demographic data, 
reproductive hormone levels and CHD risk factors had been 
measured 5 years earlier. Results indicated that overall and 
in the group aged 30–44 years, no difference was noted in 
mean carotid IMT between cases and controls; however 
women aged  45 years had greater IMT than controls 
(0.78 mm vs 70 mm) and this remained after adjustment for 
age and BMI. When additional risk factors were added in the 
regression model, fasting insulin and waist: hip ratio appeared 
to attenuate the relationship of PCOS and IMT suggesting 
that at least part of the observed associated may be driven 
Table 4 Logistic regression models of CAC ( 10 vs 10+) with CHD risk factors in PCOS cases and controls adjusted for age and 
BMI (N = 315) 
Models  β  SE  OR  95% CI for OR  p Value
1. PCOS  0.643  0.309  1.90  1.04–3.48  0.037
2. PCOS  0.605  0.312  1.83  0.99–3.38  0.053
   HDLT  −0.018 0.011  0.98  0.96–1.00  0.101
3. PCOS  0.614  0.315  1.85  1.00–3.42  0.051
   Fasting glucose  0.037  0.014  1.04  1.01–1.07  0.009
4. PCOS  0.667  0.311  1.95  1.06–3.58  0.032
   Menopausal status         
Premenopausal (baseline)      1.00   
Natural menopause  0.490  0.457  3.70  1.4–9.6  0.008
Surgical menopause  0.550  0.509  3.13  1.1–9.14  0.037
Table 5 Logistic regression models of CAC ( 10 vs 10+) with CHD risk factors in PCOS cases adjusted for age and BMI 
(N = 149) – (PCOS cases only)
Models   β  SE  OR  95% CI for OR  p Value
1. Age  0.198  0.058  1.22  1.09–1.36  0.001
   BMI  0.377  0.063  1.46  1.29–1.65   0.001
2. Age  0.201  0.058  1.22  1.09–1.37  0.001
   BMI  0.394  0.070  1.48  1.29–1.70   0.001
   HDLT  0.011  0.017  1.01  0.98–1.05  0.524
3. Age  0.171  0.060  1.19  1.05–1.34  0.004
   BMI  0.342  0.063  1.41  1.24–1.59   0.001
   Fasting glucose  0.060  0.031  1.06  1.00–1.13  0.057
4. Age  0.047  0.047  1.048  0.84–1.07  0.310
   BMI  0.182  0.033  1.20  1.127–1.33   0.001
   Menopausal status         
Premenopausal (baseline)      1.00   
Natural menopause  0.973  0.666  2.65  0.72–9.8  0.144
Surgical menopause  2.26  0.811  9.64  1.96–47.2  0.005Vascular Health and Risk Management 2008:4(2) 461
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Table 6 Logistic regression models of CAC ( 10 vs 10+) with CHD risk factors in controls adjusted for age and BMI (N = 166) 
Model   β  SE  OR  95% CI for OR  p Value
1. Age  0.063  0.032  1.07  1.00–1.13  0.048
   BMI  0.217  0.039  1.24  1.15–1.34   0.001
2. Age  0.086  0.034  1.09  1.02–1.16  0.012
   BMI  0.202  0.040  1.22  1.13–1.32   0.001
   HDLT  −0.033 0.015  0.97  0.94–1.00  0.030
3. Age  0.065  0.032  1.07  1.00–1.14  0.046
   BMI  0.210  0.040  1.23  1.14–1.33   0.001
   Fasting glucose  0.025  0.016  1.02  0.99–1.06   0.134
4. Age  −0.052  0.062 0.949 0.84–1.07  0.339
   BMI  0.205  0.044  1.227  1.13–1.34   0.001
   Menopausal status         
Premenopausal (baseline)      1.00   
Natural menopause  1.54  0.783  4.7  1.01–21.7  0.049
Surgical menopause  0.397  0.911  1.5  0.25–8.19  0.662
by central obesity and insulin resistance. Investigators have 
speculated that exposure at an early age to an adverse cardio-
vascular proﬁ  le as observed among women with PCOS leads 
to premature atherosclerotic changes. In summary, recent 
work in various and methodologies appears to conﬁ  rm our 
previous ﬁ  nding of increased SCA in women with PCOS in 
both the coronary and carotid vasculature.
This was the ﬁ  rst investigation to consider the effect of 
subclinical atherosclerosis in women with PCOS and similar 
aged controls as they undergo the menopausal transition. 
PCOS continues to be an independent risk factor for SCA 
after adjustment for age, BMI and menopausal status. Age 
is extremely correlated with menopausal status; and when 
considered in a multiple regression most likely reduced the 
signiﬁ  cance of the effect of “natural” menopause in cases. 
It is noteworthy that within the 45–54 and 55+ age strata 
the surgical menopause group of both cases and controls 
exhibited the most pronounced increased median CAC 
values. The possible interaction of menopause and CAC in 
women with PCOS warrants further investigation. The age 
at which cases and controls underwent surgical menopause 
was relatively young and is indicative of further loss of the 
coronary protection afforded normally menstruating women. 
Time since menopause was the greatest among the surgical 
menopause group giving greater credence to this ﬁ  nding. The 
scientiﬁ  c assumption has been that “the offending organ” 
the ovaries, which for a PCOS woman’s lifetime produced 
the classic symptoms of hyperandrogenemia and metabolic 
derangement, would at menopause, be less likely to lead 
to additional cardiovascular and metabolic damage. The 
paradox of the present ﬁ  ndings, ie, signiﬁ  cant increased CAC 
levels in menopausal cases versus controls of similar age 
challenges this view. The implication is that the menopausal 
transition coupled with the lifelong increase in cardiovascular 
risk factors (obesity, hyperinsulinemia, increased LDL and 
decreased HDLT) continues to create an adverse environment 
and a process in women with PCOS that outpaces those of 
non-PCOS women.
A possible bias with regard to the PCOS group is the 
presence of chronic anovulation history in which no or very 
few periods are the norm rather than the rule. We determined 
that there was one PCOS case that was regularly anovulatory, 
ie, had few or no periods throughout her reproductive years. 
It will important to determine if these results are replicated 
in other populations of middle aged women with PCOS as 
well as in further follow up of this cohort as they transition 
through menopause.
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